These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 7920321)

  • 1. Late development of graft-versus-host disease in an autologous BMT recipient.
    Appleton AL; Sviland L; Wilkes J; Pearson AD; Malcolm AJ
    Bone Marrow Transplant; 1994 Jun; 13(6):823-5. PubMed ID: 7920321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lichenoid graft-vs-host disease in an autologous bone marrow transplant recipient.
    Martin RW; Farmer ER; Altomonte VL; Vogelsang GB; Santos GW
    Arch Dermatol; 1995 Mar; 131(3):333-5. PubMed ID: 7887664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human herpes virus-6 infection in marrow graft recipients: role in pathogenesis of graft-versus-host disease. Newcastle upon Tyne Bone Marrow Transport Group.
    Appleton AL; Sviland L; Peiris JS; Taylor CE; Wilkes J; Green MA; Pearson AD; Kelly PJ; Malcolm AJ; Proctor SJ
    Bone Marrow Transplant; 1995 Dec; 16(6):777-82. PubMed ID: 8750269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helper T-lymphocyte precursor frequency predicts the occurrence of graft-versus-host disease and disease relapse after allogeneic bone marrow transplantation from HLA-identical siblings.
    Leung AY; Kwok J; Lie AK; Chen P; Chen FE; Liang R
    Haematologica; 2001 Jun; 86(6):652-6. PubMed ID: 11418376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
    Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation.
    Ladenstein R; Lasset C; Hartmann O; Klingebiel T; Bouffet E; Gadner H; Paolucci P; Burdach S; Chauvin F; Pinkerton R
    Bone Marrow Transplant; 1994 Jul; 14(1):37-46. PubMed ID: 7951119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bloodstream infections can develop late (after day 100) and/or in the absence of neutropenia in children receiving allogeneic bone marrow transplantation.
    Romano V; Castagnola E; Dallorso S; Lanino E; Calvi A; Silvestro S; Morreale G; Giacchino R; Dini G
    Bone Marrow Transplant; 1999 Feb; 23(3):271-5. PubMed ID: 10084259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT.
    Solano C; Martinez C; Brunet S; Tomás JF; Urbano-Ispizua A; Zuazu J; Ojeda E; Bargay J; Moraleda JM; Bailen A; Sierra J; García-Conde J; Rozman C
    Bone Marrow Transplant; 1998 Dec; 22(12):1129-35. PubMed ID: 9894714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late onset post-transplantation lymphoproliferative disease of recipient origin following cytogenetic relapse and occult autologous haematopoietic regeneration after allogeneic bone marrow transplantation for acute myeloid leukaemia.
    Au WY; Lie AK; Lee CK; Ma SK; Wan TS; Shek TW; Liang R; Kwong YL
    Bone Marrow Transplant; 2001 Aug; 28(4):417-9. PubMed ID: 11571518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated serum HLA class I levels coincide with acute and chronic graft-versus-host disease.
    Liem LM; Koelman CA; Doxiadis II; van Houwelingen JC; Goulmy E; Claas FH
    Bone Marrow Transplant; 1997 Aug; 20(3):227-34. PubMed ID: 9257891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimerism and tolerance: from freemartin cattle and neonatal mice to humans.
    Jankowski RA; Ildstad ST
    Hum Immunol; 1997 Feb; 52(2):155-61. PubMed ID: 9077564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation.
    Spinelli S; Chiodi S; Costantini S; Van Lint MT; Raiola AM; Ravera GB; Bacigalupo A
    Haematologica; 2003 Oct; 88(10):1163-8. PubMed ID: 14555313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
    Gadisseur AP; Gratama JW; Lamers C; van Esser JW; Bolhuis RL; Cornelissen JJ
    Bone Marrow Transplant; 1999 May; 23(10):1013-7. PubMed ID: 10373067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
    Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S
    Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
    Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
    Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation.
    Ochs LA; Miller WJ; Filipovich AH; Haake RJ; McGlave PB; Blazar BR; Ramsay NK; Kersey JH; Weisdorf DJ
    Bone Marrow Transplant; 1994 Apr; 13(4):455-60. PubMed ID: 8019471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.
    Ozawa S; Nakaseko C; Nishimura M; Maruta A; Cho R; Ohwada C; Sakamaki H; Sao H; Mori S; Okamoto S; Miyamura K; Kato S; Kawase T; Morishima Y; Kodera Y;
    Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactin: a possible mediator of graft-versus-host disease following allogeneic bone marrow transplantation in humans.
    Hinterberger-Fischer M; Kier P; Spona J; Sebesta C; Tiefengraber E; Habertheuer KH; Ruckser R; Schmid A; Kalhs P; Lechner K
    Bone Marrow Transplant; 1994 Sep; 14(3):403-6. PubMed ID: 7994262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary function changes 100 days and one year after bone marrow transplantation.
    Badier M; Guillot C; Delpierre S; Vanuxem P; Blaise D; Maraninchi D
    Bone Marrow Transplant; 1993 Nov; 12(5):457-61. PubMed ID: 8298556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberculosis in bone marrow transplant recipients: report of two cases and review of the literature.
    Martino R; Martínez C; Brunet S; Sureda A; López R; Domingo-Albós A
    Bone Marrow Transplant; 1996 Oct; 18(4):809-12. PubMed ID: 8899202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.